Canopy acquires gene-editing technology license – St. Louis Business Journal

Stunning Contemporary Gem

Dave Smoller co-founded Canopy Biosciences

Dilip Vishwanat

Canopy Biosciences, a young startup looking to accelerate the commercialization of life science medical tools and services, has exclusively licensed a gene-editing technology from Washington University in St. Louis and Johns Hopkins University.

The company, which raised$2 million from investors earlier this year, was co-founded by Dave Smoller and is led by CEO and President Edward Weinstein. Smoller and Weinstein worked together at Sigma-Aldrich before the company was sold to Merck KGaA in November 2015 for $17 billion.

Dave Smoller co-founded Canopy Biosciences

Dilip Vishwanat

Canopy looks to in-license essentially a collaboration agreement between two parties in which one company performs research and development technologies in the fields of genetic engineering and personalized medicine.

The licensed technology is called Tunr and it targets translation elongation by introducing consecutive adenosine nucleotides into a gene coding sequence of interest, according to a release.

Excerpt from:
Canopy acquires gene-editing technology license - St. Louis Business Journal